New drug shows promise for rare eye muscle disease in Long-Term trial

This study looks at the long-term safety and effectiveness of a drug called rozanolixizumab for adults with ocular myasthenia gravis, a condition that causes muscle weakness in the eyes. About 100 people who have already taken the drug in a previous study will continue treatment. The main goal is to track side effects and see if the drug helps control symptoms over time.